HSF1 and amyotrophic lateral sclerosis: As we showed that M102 is a strong activator of the HSF1 pathway, we set out to investigate whether M102 treatment has a beneficial effect on the reduction of misfolded SOD1 and TDP-43 proteinopathy, two hallmarks of ALS pathology [45, 46].